Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 27 | 2024 | 4907 | 3.730 |
Why?
|
Terminal Care | 26 | 2024 | 1773 | 3.240 |
Why?
|
Genital Neoplasms, Female | 7 | 2024 | 539 | 1.840 |
Why?
|
Hospice Care | 14 | 2023 | 679 | 1.670 |
Why?
|
Peritoneal Neoplasms | 3 | 2024 | 715 | 1.640 |
Why?
|
Caregivers | 16 | 2024 | 2303 | 1.440 |
Why?
|
Quality of Life | 25 | 2024 | 13503 | 1.150 |
Why?
|
Neoplasms | 33 | 2024 | 22385 | 1.140 |
Why?
|
Fatigue | 5 | 2024 | 1555 | 1.050 |
Why?
|
Femoracetabular Impingement | 2 | 2020 | 180 | 1.010 |
Why?
|
Patient Preference | 6 | 2022 | 947 | 0.930 |
Why?
|
Endometrial Neoplasms | 5 | 2022 | 1382 | 0.900 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2018 | 489 | 0.900 |
Why?
|
Telemedicine | 5 | 2024 | 3107 | 0.840 |
Why?
|
Terminally Ill | 6 | 2016 | 240 | 0.810 |
Why?
|
Exercise Therapy | 3 | 2020 | 941 | 0.800 |
Why?
|
Analgesics, Opioid | 4 | 2023 | 3836 | 0.800 |
Why?
|
Rosa | 1 | 2021 | 8 | 0.790 |
Why?
|
Uterine Cervical Neoplasms | 7 | 2021 | 2044 | 0.780 |
Why?
|
Neoadjuvant Therapy | 6 | 2018 | 2909 | 0.730 |
Why?
|
Medical History Taking | 2 | 2021 | 776 | 0.700 |
Why?
|
Antineoplastic Agents | 8 | 2022 | 13697 | 0.680 |
Why?
|
Hip | 1 | 2021 | 255 | 0.670 |
Why?
|
Feasibility Studies | 4 | 2024 | 5313 | 0.670 |
Why?
|
Hospices | 4 | 2017 | 245 | 0.650 |
Why?
|
Sexual Dysfunctions, Psychological | 2 | 2019 | 193 | 0.650 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2022 | 9433 | 0.650 |
Why?
|
Platinum Compounds | 1 | 2019 | 95 | 0.630 |
Why?
|
Patient-Centered Care | 4 | 2024 | 1447 | 0.610 |
Why?
|
Focus Groups | 2 | 2024 | 1453 | 0.610 |
Why?
|
Genetic Testing | 2 | 2022 | 3587 | 0.590 |
Why?
|
Palliative Care | 10 | 2023 | 3643 | 0.560 |
Why?
|
Arthralgia | 1 | 2021 | 459 | 0.560 |
Why?
|
Genetic Counseling | 1 | 2020 | 634 | 0.540 |
Why?
|
Advance Care Planning | 7 | 2024 | 698 | 0.540 |
Why?
|
Allied Health Personnel | 1 | 2018 | 156 | 0.530 |
Why?
|
Pilot Projects | 7 | 2024 | 8731 | 0.520 |
Why?
|
Female | 90 | 2024 | 397089 | 0.510 |
Why?
|
Insurance, Health | 5 | 2022 | 2518 | 0.500 |
Why?
|
Sports | 1 | 2021 | 703 | 0.490 |
Why?
|
Cost of Illness | 2 | 2022 | 1959 | 0.490 |
Why?
|
Humans | 116 | 2024 | 768393 | 0.480 |
Why?
|
Bereavement | 3 | 2022 | 310 | 0.480 |
Why?
|
Death | 5 | 2023 | 683 | 0.470 |
Why?
|
SEER Program | 7 | 2021 | 1474 | 0.460 |
Why?
|
CA-125 Antigen | 1 | 2016 | 281 | 0.460 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2017 | 365 | 0.440 |
Why?
|
Insurance Coverage | 4 | 2021 | 1946 | 0.440 |
Why?
|
Aged | 49 | 2024 | 171562 | 0.430 |
Why?
|
Physician-Patient Relations | 7 | 2024 | 3267 | 0.430 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2017 | 794 | 0.430 |
Why?
|
Patient Compliance | 2 | 2020 | 2693 | 0.420 |
Why?
|
Exercise | 2 | 2021 | 5946 | 0.420 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2019 | 3553 | 0.410 |
Why?
|
Research Support as Topic | 1 | 2017 | 696 | 0.410 |
Why?
|
Workload | 1 | 2018 | 852 | 0.390 |
Why?
|
Middle Aged | 50 | 2024 | 223491 | 0.390 |
Why?
|
Acculturation | 1 | 2013 | 179 | 0.380 |
Why?
|
Physical Therapy Modalities | 2 | 2016 | 533 | 0.380 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2021 | 1189 | 0.370 |
Why?
|
Public Health Administration | 1 | 2013 | 242 | 0.370 |
Why?
|
Athletic Injuries | 1 | 2021 | 1245 | 0.370 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7453 | 0.360 |
Why?
|
Spouses | 2 | 2024 | 286 | 0.360 |
Why?
|
Curriculum | 1 | 2024 | 3776 | 0.350 |
Why?
|
Adult | 38 | 2024 | 223640 | 0.330 |
Why?
|
Self Efficacy | 3 | 2024 | 643 | 0.330 |
Why?
|
Family | 3 | 2024 | 3208 | 0.330 |
Why?
|
Research | 1 | 2018 | 1981 | 0.320 |
Why?
|
Medical Oncology | 6 | 2023 | 2349 | 0.320 |
Why?
|
Health Services Accessibility | 3 | 2021 | 5512 | 0.320 |
Why?
|
Burnout, Professional | 1 | 2018 | 712 | 0.320 |
Why?
|
Reoperation | 1 | 2019 | 4341 | 0.310 |
Why?
|
Patient Education as Topic | 2 | 2021 | 2337 | 0.300 |
Why?
|
United States | 25 | 2023 | 73150 | 0.300 |
Why?
|
Qualitative Research | 6 | 2024 | 3131 | 0.300 |
Why?
|
Attitude to Death | 6 | 2011 | 401 | 0.300 |
Why?
|
Oncogenes | 1 | 2013 | 1235 | 0.290 |
Why?
|
Circumcision, Male | 1 | 2008 | 148 | 0.280 |
Why?
|
International Cooperation | 1 | 2013 | 1438 | 0.280 |
Why?
|
Medicare | 9 | 2023 | 6881 | 0.270 |
Why?
|
Osteoarthritis, Hip | 1 | 2011 | 409 | 0.270 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11254 | 0.260 |
Why?
|
Tobacco Industry | 1 | 2007 | 138 | 0.260 |
Why?
|
Communication | 7 | 2024 | 3912 | 0.250 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2005 | 102 | 0.250 |
Why?
|
Adult Children | 2 | 2024 | 104 | 0.240 |
Why?
|
Antitrust Laws | 1 | 2004 | 8 | 0.240 |
Why?
|
Nursing Care | 1 | 2005 | 65 | 0.240 |
Why?
|
Marketing | 1 | 2007 | 224 | 0.240 |
Why?
|
Abortion, Legal | 1 | 2006 | 120 | 0.240 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2013 | 2202 | 0.240 |
Why?
|
Biomedical Research | 2 | 2018 | 3464 | 0.240 |
Why?
|
Medication Systems, Hospital | 1 | 2005 | 154 | 0.240 |
Why?
|
Psychotherapy, Group | 2 | 2019 | 414 | 0.230 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2006 | 239 | 0.230 |
Why?
|
Students, Health Occupations | 1 | 2024 | 30 | 0.230 |
Why?
|
Prospective Studies | 13 | 2021 | 54920 | 0.220 |
Why?
|
Relief Work | 1 | 2004 | 131 | 0.220 |
Why?
|
Medically Uninsured | 2 | 2021 | 841 | 0.220 |
Why?
|
Life Expectancy | 4 | 2020 | 1249 | 0.210 |
Why?
|
Aged, 80 and over | 13 | 2022 | 59686 | 0.210 |
Why?
|
Program Evaluation | 2 | 2024 | 2505 | 0.210 |
Why?
|
Personnel Selection | 1 | 2004 | 201 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2016 | 876 | 0.200 |
Why?
|
Salaries and Fringe Benefits | 1 | 2004 | 262 | 0.200 |
Why?
|
Early Detection of Cancer | 3 | 2023 | 3236 | 0.200 |
Why?
|
Adaptation, Psychological | 6 | 2024 | 2663 | 0.190 |
Why?
|
Stress, Psychological | 1 | 2017 | 4543 | 0.190 |
Why?
|
Male | 41 | 2024 | 364902 | 0.190 |
Why?
|
Hip Joint | 2 | 2020 | 1018 | 0.190 |
Why?
|
Physician's Role | 2 | 2024 | 926 | 0.190 |
Why?
|
Drug Prescriptions | 2 | 2021 | 1673 | 0.190 |
Why?
|
Quality of Health Care | 2 | 2016 | 4339 | 0.190 |
Why?
|
Patient Satisfaction | 4 | 2018 | 3486 | 0.190 |
Why?
|
Papillomaviridae | 2 | 2013 | 1140 | 0.190 |
Why?
|
Pyrimidinones | 2 | 2021 | 386 | 0.190 |
Why?
|
HIV Infections | 5 | 2015 | 17575 | 0.180 |
Why?
|
Colorectal Neoplasms | 2 | 2023 | 6971 | 0.180 |
Why?
|
Adenocarcinoma | 3 | 2018 | 6406 | 0.180 |
Why?
|
Viral Vaccines | 1 | 2006 | 596 | 0.180 |
Why?
|
Nurse's Role | 1 | 2022 | 188 | 0.180 |
Why?
|
Self Care | 1 | 2006 | 797 | 0.180 |
Why?
|
Survival Rate | 7 | 2021 | 12870 | 0.180 |
Why?
|
Mental Health | 3 | 2010 | 3276 | 0.170 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 433 | 0.170 |
Why?
|
Ovarian Cysts | 1 | 2020 | 108 | 0.170 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 26375 | 0.170 |
Why?
|
Delivery of Health Care | 1 | 2018 | 5375 | 0.170 |
Why?
|
Physicians | 1 | 2018 | 4614 | 0.170 |
Why?
|
Young Adult | 9 | 2024 | 60049 | 0.170 |
Why?
|
Public Health | 2 | 2017 | 2682 | 0.170 |
Why?
|
Shoulder | 1 | 2021 | 301 | 0.170 |
Why?
|
Combined Modality Therapy | 4 | 2021 | 8562 | 0.160 |
Why?
|
Medication Errors | 1 | 2005 | 784 | 0.160 |
Why?
|
Attitude of Health Personnel | 3 | 2024 | 3922 | 0.160 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12558 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 11854 | 0.160 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2021 | 348 | 0.160 |
Why?
|
Spirituality | 4 | 2011 | 430 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2013 | 4069 | 0.150 |
Why?
|
Medicare Part D | 1 | 2023 | 358 | 0.150 |
Why?
|
Lung Neoplasms | 3 | 2023 | 13576 | 0.150 |
Why?
|
Resistance Training | 1 | 2020 | 199 | 0.150 |
Why?
|
Leadership | 2 | 2018 | 1395 | 0.150 |
Why?
|
Colorado | 1 | 2018 | 167 | 0.150 |
Why?
|
Yoga | 1 | 2021 | 280 | 0.150 |
Why?
|
Delayed Diagnosis | 1 | 2022 | 469 | 0.140 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1339 | 0.140 |
Why?
|
Health Services Administration | 1 | 2018 | 63 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 1 | 2022 | 1064 | 0.140 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2020 | 329 | 0.140 |
Why?
|
Patients | 1 | 2023 | 909 | 0.140 |
Why?
|
Obesity | 3 | 2017 | 13084 | 0.140 |
Why?
|
Goals | 1 | 2022 | 716 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10377 | 0.140 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2021 | 480 | 0.130 |
Why?
|
Health Expenditures | 3 | 2019 | 2395 | 0.130 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2024 | 959 | 0.130 |
Why?
|
Psychotherapy, Brief | 1 | 2017 | 118 | 0.130 |
Why?
|
Drug Therapy | 1 | 2019 | 504 | 0.130 |
Why?
|
Time Factors | 6 | 2021 | 40272 | 0.130 |
Why?
|
Health Policy | 1 | 2008 | 2698 | 0.130 |
Why?
|
Intensive Care Units | 3 | 2016 | 3801 | 0.130 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2021 | 716 | 0.120 |
Why?
|
Medicaid | 2 | 2021 | 2842 | 0.120 |
Why?
|
Papillomavirus Infections | 2 | 2013 | 1640 | 0.120 |
Why?
|
Budgets | 1 | 2017 | 232 | 0.120 |
Why?
|
Drug Utilization | 1 | 2021 | 1191 | 0.120 |
Why?
|
Leukemia | 1 | 2023 | 1526 | 0.120 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2019 | 622 | 0.120 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 413 | 0.120 |
Why?
|
Infusions, Intravenous | 2 | 2020 | 2226 | 0.120 |
Why?
|
Disease-Free Survival | 3 | 2020 | 6856 | 0.120 |
Why?
|
Efficiency | 1 | 2018 | 477 | 0.120 |
Why?
|
Propensity Score | 2 | 2019 | 1962 | 0.120 |
Why?
|
Science | 1 | 2017 | 237 | 0.120 |
Why?
|
Cohort Studies | 9 | 2021 | 41795 | 0.110 |
Why?
|
South Africa | 3 | 2015 | 1871 | 0.110 |
Why?
|
Telephone | 1 | 2017 | 630 | 0.110 |
Why?
|
Job Satisfaction | 1 | 2018 | 549 | 0.110 |
Why?
|
Athletes | 1 | 2021 | 1162 | 0.110 |
Why?
|
Hospitalization | 3 | 2022 | 10844 | 0.110 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 713 | 0.110 |
Why?
|
Natural Language Processing | 2 | 2019 | 1202 | 0.110 |
Why?
|
Developing Countries | 1 | 2006 | 2903 | 0.110 |
Why?
|
Pyrazoles | 2 | 2021 | 2021 | 0.110 |
Why?
|
Efficiency, Organizational | 1 | 2018 | 700 | 0.110 |
Why?
|
Depression | 3 | 2024 | 8241 | 0.100 |
Why?
|
Withholding Treatment | 2 | 2015 | 620 | 0.100 |
Why?
|
Documentation | 1 | 2019 | 917 | 0.100 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 163 | 0.100 |
Why?
|
Mutation | 3 | 2013 | 30228 | 0.100 |
Why?
|
Health Maintenance Organizations | 1 | 2015 | 658 | 0.100 |
Why?
|
MutS Homolog 2 Protein | 1 | 2012 | 200 | 0.100 |
Why?
|
Critical Care | 2 | 2016 | 2716 | 0.100 |
Why?
|
Uterine Neoplasms | 1 | 2021 | 1427 | 0.100 |
Why?
|
Single-Blind Method | 1 | 2016 | 1585 | 0.100 |
Why?
|
Prognosis | 5 | 2023 | 30022 | 0.100 |
Why?
|
Treatment Refusal | 1 | 2015 | 432 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2433 | 0.100 |
Why?
|
Cell Cycle Proteins | 2 | 2021 | 3458 | 0.090 |
Why?
|
Cancer Care Facilities | 2 | 2013 | 424 | 0.090 |
Why?
|
Survival Analysis | 5 | 2019 | 10117 | 0.090 |
Why?
|
Muscle Strength | 1 | 2016 | 641 | 0.090 |
Why?
|
Delphi Technique | 1 | 2015 | 888 | 0.090 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 494 | 0.090 |
Why?
|
Motivation | 1 | 2021 | 2029 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2021 | 1813 | 0.090 |
Why?
|
Evidence-Based Practice | 1 | 2015 | 500 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5422 | 0.090 |
Why?
|
Religion and Medicine | 2 | 2009 | 161 | 0.090 |
Why?
|
Africa South of the Sahara | 1 | 2013 | 751 | 0.090 |
Why?
|
Fee-for-Service Plans | 1 | 2016 | 714 | 0.090 |
Why?
|
Fertility | 1 | 2015 | 772 | 0.090 |
Why?
|
Meningeal Neoplasms | 1 | 2019 | 1253 | 0.090 |
Why?
|
Anxiety Disorders | 2 | 2020 | 2754 | 0.090 |
Why?
|
Smoking | 1 | 2007 | 9111 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3231 | 0.090 |
Why?
|
Mass Screening | 1 | 2006 | 5451 | 0.090 |
Why?
|
Vagina | 1 | 2015 | 845 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2884 | 0.080 |
Why?
|
Phthalazines | 2 | 2022 | 397 | 0.080 |
Why?
|
Information Dissemination | 1 | 2018 | 1137 | 0.080 |
Why?
|
Faculty, Medical | 1 | 2018 | 1218 | 0.080 |
Why?
|
Advance Directives | 1 | 2011 | 249 | 0.080 |
Why?
|
Disclosure | 1 | 2015 | 754 | 0.080 |
Why?
|
Spiritual Therapies | 1 | 2009 | 60 | 0.080 |
Why?
|
Adolescent | 7 | 2019 | 89184 | 0.080 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 1599 | 0.080 |
Why?
|
Emergency Service, Hospital | 2 | 2021 | 7955 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 906 | 0.080 |
Why?
|
Radiation Oncology | 1 | 2015 | 573 | 0.080 |
Why?
|
Health Resources | 1 | 2015 | 950 | 0.080 |
Why?
|
Attitude to Health | 2 | 2015 | 2025 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 594 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4266 | 0.080 |
Why?
|
DNA Mutational Analysis | 2 | 2013 | 4120 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6541 | 0.070 |
Why?
|
Brachytherapy | 1 | 2015 | 1226 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3627 | 0.070 |
Why?
|
Length of Stay | 2 | 2014 | 6519 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12092 | 0.070 |
Why?
|
Papillomavirus Vaccines | 1 | 2013 | 497 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20224 | 0.070 |
Why?
|
History, 20th Century | 2 | 2004 | 2771 | 0.070 |
Why?
|
Patient Care Team | 1 | 2018 | 2529 | 0.070 |
Why?
|
Product Labeling | 1 | 2007 | 76 | 0.070 |
Why?
|
Africa | 1 | 2008 | 726 | 0.070 |
Why?
|
Gene Frequency | 1 | 2013 | 3617 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9261 | 0.070 |
Why?
|
Prevalence | 2 | 2021 | 15872 | 0.060 |
Why?
|
Computer User Training | 1 | 2005 | 19 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 13020 | 0.060 |
Why?
|
Health Care Surveys | 1 | 2013 | 2437 | 0.060 |
Why?
|
Health Status | 1 | 2018 | 4094 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3283 | 0.060 |
Why?
|
Pain Measurement | 1 | 2016 | 3581 | 0.060 |
Why?
|
Consensus | 1 | 2015 | 3212 | 0.060 |
Why?
|
Education, Nursing, Continuing | 1 | 2005 | 69 | 0.060 |
Why?
|
Child of Impaired Parents | 1 | 2009 | 463 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2024 | 15939 | 0.060 |
Why?
|
Afghanistan | 1 | 2004 | 77 | 0.060 |
Why?
|
Iraq | 1 | 2004 | 92 | 0.060 |
Why?
|
Taxes | 1 | 2007 | 220 | 0.060 |
Why?
|
Hospitals, Military | 1 | 2004 | 62 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2016 | 5367 | 0.060 |
Why?
|
Supreme Court Decisions | 1 | 2006 | 135 | 0.060 |
Why?
|
Endometriosis | 1 | 2012 | 875 | 0.060 |
Why?
|
Device Approval | 1 | 2006 | 164 | 0.060 |
Why?
|
Internship and Residency | 1 | 2004 | 5949 | 0.060 |
Why?
|
Resuscitation | 1 | 2008 | 679 | 0.060 |
Why?
|
Sex Factors | 1 | 2018 | 10654 | 0.060 |
Why?
|
Organizations | 1 | 2004 | 172 | 0.060 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1794 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21162 | 0.050 |
Why?
|
Resuscitation Orders | 3 | 2011 | 271 | 0.050 |
Why?
|
False Positive Reactions | 1 | 2006 | 962 | 0.050 |
Why?
|
Logistic Models | 3 | 2018 | 13323 | 0.050 |
Why?
|
Disease Transmission, Infectious | 1 | 2008 | 562 | 0.050 |
Why?
|
Vaginal Smears | 1 | 2006 | 505 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2018 | 4875 | 0.050 |
Why?
|
Hospital Information Systems | 1 | 2005 | 394 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2022 | 65379 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1905 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 89 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3413 | 0.050 |
Why?
|
Homicide | 1 | 2004 | 294 | 0.050 |
Why?
|
Health Care Costs | 2 | 2019 | 3267 | 0.050 |
Why?
|
Commerce | 1 | 2007 | 612 | 0.050 |
Why?
|
Internationality | 1 | 2007 | 1008 | 0.050 |
Why?
|
Primary Prevention | 1 | 2008 | 1187 | 0.050 |
Why?
|
Saliva | 1 | 2006 | 854 | 0.050 |
Why?
|
China | 1 | 2007 | 2395 | 0.050 |
Why?
|
World Health Organization | 1 | 2007 | 1327 | 0.050 |
Why?
|
Genome, Human | 1 | 2013 | 4450 | 0.040 |
Why?
|
Abortion, Induced | 1 | 2006 | 475 | 0.040 |
Why?
|
Preventive Health Services | 1 | 2004 | 568 | 0.040 |
Why?
|
Decision Making | 3 | 2024 | 3953 | 0.040 |
Why?
|
Disease Progression | 2 | 2020 | 13646 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 60 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2021 | 423 | 0.040 |
Why?
|
Models, Statistical | 1 | 2013 | 5099 | 0.040 |
Why?
|
HIV Antibodies | 1 | 2006 | 1341 | 0.040 |
Why?
|
Genotype | 1 | 2013 | 13042 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18048 | 0.040 |
Why?
|
Biomedical Technology | 1 | 2021 | 210 | 0.040 |
Why?
|
Health Services for the Aged | 1 | 2021 | 258 | 0.040 |
Why?
|
History, 21st Century | 1 | 2004 | 1575 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2010 | 14784 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 2588 | 0.040 |
Why?
|
Religion and Psychology | 2 | 2010 | 180 | 0.040 |
Why?
|
Politics | 1 | 2004 | 821 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 252 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2019 | 81801 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 755 | 0.040 |
Why?
|
Cost Control | 1 | 2019 | 627 | 0.030 |
Why?
|
Hospitals | 1 | 2010 | 3906 | 0.030 |
Why?
|
Syndrome | 1 | 2023 | 3275 | 0.030 |
Why?
|
Women's Health | 1 | 2006 | 2078 | 0.030 |
Why?
|
Administrative Personnel | 1 | 2018 | 185 | 0.030 |
Why?
|
Uncertainty | 1 | 2021 | 759 | 0.030 |
Why?
|
Models, Economic | 1 | 2019 | 718 | 0.030 |
Why?
|
Research Design | 2 | 2021 | 6210 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1195 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1975 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2247 | 0.030 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 135 | 0.030 |
Why?
|
Core Binding Factor beta Subunit | 1 | 2013 | 42 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 904 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10588 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 818 | 0.030 |
Why?
|
E1A-Associated p300 Protein | 1 | 2013 | 125 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20765 | 0.030 |
Why?
|
Research Personnel | 1 | 2018 | 590 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2013 | 314 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2013 | 4921 | 0.030 |
Why?
|
HLA-B Antigens | 1 | 2013 | 328 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4859 | 0.030 |
Why?
|
Harm Reduction | 1 | 2013 | 143 | 0.020 |
Why?
|
F-Box Proteins | 1 | 2013 | 201 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 478 | 0.020 |
Why?
|
Social Isolation | 1 | 2015 | 369 | 0.020 |
Why?
|
Virus Integration | 1 | 2013 | 306 | 0.020 |
Why?
|
Risk Factors | 3 | 2013 | 74962 | 0.020 |
Why?
|
Health Education | 1 | 2018 | 1057 | 0.020 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2013 | 378 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14737 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2460 | 0.020 |
Why?
|
Databases, Factual | 2 | 2016 | 8075 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3766 | 0.020 |
Why?
|
Life Support Care | 1 | 2011 | 226 | 0.020 |
Why?
|
Sex Offenses | 1 | 2013 | 358 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 4047 | 0.020 |
Why?
|
Social Stigma | 1 | 2015 | 785 | 0.020 |
Why?
|
Family Characteristics | 1 | 2013 | 1003 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10776 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5103 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2013 | 666 | 0.020 |
Why?
|
Patient Transfer | 1 | 2014 | 793 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1076 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39407 | 0.020 |
Why?
|
Sex Distribution | 1 | 2012 | 2281 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 4039 | 0.020 |
Why?
|
Age Distribution | 1 | 2012 | 2877 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3541 | 0.020 |
Why?
|
Child | 3 | 2013 | 80891 | 0.020 |
Why?
|
Heterozygote | 1 | 2012 | 2791 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5336 | 0.020 |
Why?
|
Social Support | 1 | 2015 | 2191 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 2046 | 0.010 |
Why?
|
Educational Status | 1 | 2012 | 2518 | 0.010 |
Why?
|
Pregnancy | 1 | 2006 | 30200 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3858 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2013 | 1901 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2482 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2011 | 2740 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2952 | 0.010 |
Why?
|
Home Care Services | 1 | 2009 | 659 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4526 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8753 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14154 | 0.010 |
Why?
|
Boston | 1 | 2012 | 9371 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13052 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21544 | 0.010 |
Why?
|
Genomics | 1 | 2013 | 5916 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8634 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 8051 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9682 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2011 | 7861 | 0.010 |
Why?
|
Critical Illness | 1 | 2009 | 2755 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9614 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23631 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 22296 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 15881 | 0.010 |
Why?
|
Transcription Factors | 1 | 2013 | 12166 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15455 | 0.010 |
Why?
|
Risk Assessment | 1 | 2009 | 24318 | 0.000 |
Why?
|
Child, Preschool | 1 | 2009 | 42650 | 0.000 |
Why?
|